A. McElhinny

Journal of Thoracic Oncology · 2002–2017

A researcher in the Science corpus: 2 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Papers from A. McElhinny's perspective

Ordered by how strongly the researchers A. McElhinny trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. (The Lancet)
  2. Pembrolizumab for the treatment of non-small-cell lung cancer. (New England Journal of Medicine)
  3. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy (Molecular Cancer Therapeutics)
  4. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer (New England Journal of Medicine)
  5. The Complete Gene Sequence of Titin, Expression of an Unusual ≈700-kDa Titin Isoform, and Its Interaction With Obscurin Identify a Novel Z-Line to I-Band Linking System
  6. Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer (New England Journal of Medicine)
  7. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. (The Lancet)
  8. Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy (Science)
  9. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. (Cell)
  10. Function and genetics of dystrophin and dystrophin-related proteins in muscle. (Physiological Reviews)

Their papers